112 related articles for article (PubMed ID: 22462133)
1. [Features and the method of application of a CCR5 antagonist, a new integrase inhibitor].
Katanaga H
Nihon Naika Gakkai Zasshi; 2009 Nov; 98(11):2802-8. PubMed ID: 22462133
[No Abstract] [Full Text] [Related]
2. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Arribas JR
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
[TBL] [Abstract][Full Text] [Related]
3. [New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
Moreno Cuerda VJ; Rubio García R; Barros Aguado C; Morales Conejo M
Rev Clin Esp; 2008 Oct; 208(9):463-6. PubMed ID: 19000475
[TBL] [Abstract][Full Text] [Related]
4. [New antiretroviral drug classes in HIV therapy].
Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
[No Abstract] [Full Text] [Related]
5. Antiretroviral treatment update from the 17th International AIDS Conference.
Boyle B; Cohen C; DeJesus E; Elion R; Frank I; Moyle G; Sax P
AIDS Read; 2008 Nov; 18(11):570-9. PubMed ID: 19062402
[No Abstract] [Full Text] [Related]
6. Anti-HIV agents. New drugs, new hope, old lessons.
TreatmentUpdate; 2007 Feb; 19(2):1-3. PubMed ID: 17447311
[No Abstract] [Full Text] [Related]
7. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Hughes A; Barber T; Nelson M
J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
[TBL] [Abstract][Full Text] [Related]
8. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
[TBL] [Abstract][Full Text] [Related]
9. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
Neff CP; Ndolo T; Tandon A; Habu Y; Akkina R
PLoS One; 2010 Dec; 5(12):e15257. PubMed ID: 21203568
[TBL] [Abstract][Full Text] [Related]
10. The clinical pharmacology of antiretrovirals in development.
Winston A; Mallon PW; Boffito M
Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):447-58. PubMed ID: 16863445
[TBL] [Abstract][Full Text] [Related]
11. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
[TBL] [Abstract][Full Text] [Related]
12. Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus.
Stephenson J
JAMA; 2007 Apr; 297(14):1535-6. PubMed ID: 17426263
[No Abstract] [Full Text] [Related]
13. A review of the clinical pharmacology of maraviroc. Introduction.
Boffito M; Abel S
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):1-4. PubMed ID: 18333860
[No Abstract] [Full Text] [Related]
14. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
Armstrong-James D; Stebbing J; Scourfield A; Smit E; Ferns B; Pillay D; Nelson M
Antiviral Res; 2010 May; 86(2):224-6. PubMed ID: 20211653
[TBL] [Abstract][Full Text] [Related]
15. CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.
Kim MB; Giesler KE; Tahirovic YA; Truax VM; Liotta DC; Wilson LJ
Expert Opin Investig Drugs; 2016 Dec; 25(12):1377-1392. PubMed ID: 27791451
[TBL] [Abstract][Full Text] [Related]
16. [The newest developments in anti-HIV-1 drugs].
Zhang XQ
Yao Xue Xue Bao; 2010 Feb; 45(2):194-204. PubMed ID: 21351429
[TBL] [Abstract][Full Text] [Related]
17. Preclinical discovery and development of maraviroc for the treatment of HIV.
Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
[TBL] [Abstract][Full Text] [Related]
18. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
19. Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.
Afonso P; Auclair M; Caron-Debarle M; Capeau J
Antivir Ther; 2017; 22(8):645-657. PubMed ID: 28350300
[TBL] [Abstract][Full Text] [Related]
20. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Maraviroc in treatment-experienced and treatment-naive patients.
AIDS Clin Care; 2007 Oct; 19(10):83-4. PubMed ID: 18401879
[No Abstract] [Full Text] [Related]
[Next] [New Search]
